Premium
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m 2 ) in combination with lenalidomide and dexamethasone
Author(s) -
Korde Neha,
Mastey Donna,
Tavitian Elizabet,
Mailankody Sham,
Lesokhin Alexander,
Hassoun Hani,
Smith Eric L.,
Lendvai Nikoletta,
Hultcrantz Malin,
Shah Urvi,
Tan Carlyn,
Lu Sydney,
Diamond Benjamin,
Salcedo Meghan,
Werner Kelly,
Chung David J.,
Scordo Michael,
Shah Gunjan L.,
Lahoud Oscar,
Landau Heather,
Arcila Maria,
Ho Caleb,
Roshal Mikhail,
Dogan Ahmet,
Derkach Andriy,
Devlin Sean M.,
Giralt Sergio A.,
Landgren Ola
Publication year - 2021
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.26150
Subject(s) - lenalidomide , carfilzomib , medicine , multiple myeloma , dexamethasone , oncology , minimal residual disease , phases of clinical research , clinical trial , surgery , bone marrow